Target volume in soft tissue sarcoma of the extremities

被引:8
作者
Faivre, J. -C. [1 ]
Le Pechoux, C. [2 ]
机构
[1] Inst Cancerol Lorraine Alexis Vautrin, Dept Univ Radiotherapie Curietherapie, F-54511 Vandoeuvre Les Nancy, France
[2] Inst Cancerol Gustave Roussy, Dept Radiotherapie, F-94800 Villejuif, France
来源
CANCER RADIOTHERAPIE | 2013年 / 17卷 / 5-6期
关键词
Soft tissue sarcoma; Conformal radiotherapy; Target volume; Extremities; POSTOPERATIVE RADIOTHERAPY; PROGNOSTIC-FACTORS; RADIATION-THERAPY; CONSERVATIVE SURGERY; ADJUVANT RADIATION; RANDOMIZED TRIAL; MANAGEMENT; OUTCOMES; TUMORS;
D O I
10.1016/j.canrad.2013.07.146
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Soft tissue sarcoma is a rare entity and heterogeneous disease and its management therefore requires an experienced multidisciplinary team in an expert center. Standard treatment for grade 2 and 3 sarcomas is a conservative, extended surgery planned according to the results of the biopsy, and radiotherapy usually administered postoperatively (or pre-operatively). The indications for preoperative radiotherapy are discussed in a multidisciplinary meeting for locally advanced tumours. The definition of target volumes for conformal radiation therapy requires a good knowledge of the patient record, radioanatomy, as well as a careful reading of surgical and histological reports. The definitions of target volumes combine anatomical and geometrical approach. The gross tumour volume is the visible tumour on MRI preoperatively. The corresponding clinical target volume is defined by a larger longitudinal automatic extension than the radial extension. It is manually corrected taking into account the anatomical barriers to tumour spread. The planning target volume is a concentric automatic margin that may vary from one institution to another, depending on the immobilisation devices and verification of repositioning. Innovative radiotherapy techniques may be used to reduce the size of the margins around target volumes and better protect the organs at risk. (C) 2013 Published by Elsevier Masson SAS on behalf of the Societe francaise de radiotherapie oncologique (SFRO).
引用
收藏
页码:444 / 452
页数:9
相关论文
共 43 条
[1]   POSITIVE SURGICAL MARGINS IN SOFT TISSUE SARCOMA TREATED WITH PREOPERATIVE RADIATION: IS A POSTOPERATIVE BOOST NECESSARY? [J].
Al Yami, Ali ;
Griffin, Anthony M. ;
Ferguson, Peter C. ;
Catton, Charles N. ;
Chung, Peter W. M. ;
Bell, Robert S. ;
Wunder, Jay S. ;
O'Sullivan, Brian .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 77 (04) :1191-1197
[2]   Adjuvant radiation for stage II-B soft tissue sarcoma of the extremity [J].
Alektiar, KM ;
Leung, D ;
Zelefsky, MJ ;
Brennan, MF .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) :1643-1650
[3]   Compartmental anatomy: Relevance to staging and biopsy of musculoskeletal tumors [J].
Anderson, MW ;
Temple, HT ;
Dussault, RG ;
Kaplan, PA .
AMERICAN JOURNAL OF ROENTGENOLOGY, 1999, 173 (06) :1663-1671
[4]  
[Anonymous], 2013, CLIN PRACT GUID ONC
[5]   Prognostic factors of extremity soft tissue sarcoma in adults. A single institutional analysis [J].
Atean, I. ;
Pointreau, Y. ;
Rosset, P. ;
Garaud, P. ;
De-Pinieux, G. ;
Calais, G. .
CANCER RADIOTHERAPIE, 2012, 16 (08) :661-666
[6]   Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk [J].
Baldini, EH ;
Goldberg, J ;
Jenner, C ;
Manola, JB ;
Demetri, GD ;
Fletcher, CDM ;
Singer, S .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) :3252-3259
[7]  
Bonvalot S, 2006, Cancer Radiother, V10, P416, DOI 10.1016/j.canrad.2006.05.015
[8]   What is new in the local approach of limb sarcomas and desmoid tumours? [J].
Bonvalot, S. ;
Rimareix, F. ;
Paumier, A. ;
Roberti, E. ;
Bouzaiene, H. ;
Le Pechoux, C. .
CANCER RADIOTHERAPIE, 2010, 14 (6-7) :455-459
[9]   Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Casali, P. G. ;
Blay, J. -Y. .
ANNALS OF ONCOLOGY, 2010, 21 :v198-v203
[10]   Primary multidisciplinary management of extremity soft tissue sarcomas [J].
Clarkson P. ;
Ferguson P.C. .
Current Treatment Options in Oncology, 2004, 5 (6) :451-462